Tag: medical education

The Most Commonly Prescribed Medication for Bipolar Disorder… But Is It the Best?

When it comes to bipolar disorder, the most commonly prescribed medication isn’t necessarily the most effective.Many clinicians default to prescribing quetiapine, valproate, or lamotrigine, yet lithium remains the gold standardfor long-term treatment.

So, why is lithium often overlooked? Despite decades of evidence supporting its unmatched efficacy in preventing relapse, reducing suicide risk, and stabilizing mood long-term, lithium is underprescribed due to concerns over side effects, monitoring requirements, and physician discomfort with its use.

🔹 What Do the RCTs Say About Lithium?

✅ BALANCE Trial (2010) – The landmark study comparing lithium vs. valproate vs. combination therapy found that lithium monotherapy was superior to valproate in preventing relapse into both manic and depressive episodes (Geddes et al., 2010).

✅ NIMH STEP-BD Trial (2005) – Among mood stabilizers, lithium significantly reduced suicide risk, a benefit not shared by other common treatments (Goodwin et al., 2003).

✅ Cade’s Legacy and Beyond – Multiple meta-analyses confirm that lithium reduces relapse rates and is the only mood stabilizer with strong anti-suicidal effects (Cipriani et al., 2005).

🚨 The Bottom Line? Lithium is STILL the most effective long-term treatment for bipolar disorder, yet it is often underutilized. Instead, newer and more expensive alternatives are frequently prescribed—even when they lack lithium’s robust evidence base.

Yes, lithium requires monitoring. Yes, it comes with side effects. But for patients with bipolar disorder, choosing the right medication can mean the difference between stability and relapse, life and death.

Let’s start prescribing based on data, not convenience. 🔥

0

The Pill Won’t Solve It All 💊🚫

When every problem you face has been treated exclusively by a pill, you start to believe that the answer to all your struggles lies in finding the right one. 🤔💡

With this mindset, you will never be well. 🧠❌

It’s no different than someone searching for the perfect car 🚗 or the dream home 🏡 to fix their life. Sure, it might bring temporary relief, but in the end, it steals your power, leaving your happiness dependent on external factors you can’t control. 🎭🔗

True healing starts when you reclaim your own agency. 💪🔥

0

📌 CANMAT Guidelines for Depression: 2023 Update

The Canadian Network for Mood and Anxiety Treatments (CANMAT) released updated guidelines in 2023 for the management of Major Depressive Disorder (MDD), reflecting recent advancements in the field.

Key Updates in the 2023 CANMAT Guidelines:

  1. Personalized Care Approach:
    • Emphasis on shared decision-making, considering patient values, preferences, and treatment history to tailor individualized treatment plans.
  2. Updated Treatment Recommendations:
    • Psychological Therapies: Continued endorsement of therapies like Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) for mild to moderate depression.
    • Pharmacological Treatments: Introduction of newer antidepressants and updated recommendations based on recent evidence.
    • Neuromodulation: Expanded guidance on treatments such as Transcranial Magnetic Stimulation (TMS)and Electroconvulsive Therapy (ECT), especially for treatment-resistant cases.
  3. Lifestyle and Complementary Interventions:
    • Recognition of the role of exercise, nutrition, and sleep in managing depression.
    • Evaluation of complementary and alternative medicine approaches, providing guidance on their efficacy and safety.
  4. Digital Health:
    • Assessment of digital interventions, including online therapy platforms and mobile applications, as supplementary tools in treatment plans.
  5. Management of Inadequate Response:
    • Strategies for addressing partial or non-response to initial treatments, including augmentation and combination therapies.

These updates underscore the importance of a collaborative and individualized approach in managing MDD, integrating the latest evidence to optimize patient outcomes.

For a comprehensive overview, refer to the full publication: 

pubmed.ncbi.nlm.nih.gov

0

💊 Are Antidepressants Overprescribed in the U.S.? 🤔

The question of whether antidepressants are overprescribed in the United States is complex and depends on how “overprescription” is defined.

Arguments Suggesting Overprescription

  1. Broad Diagnostic Criteria:
    • The criteria for diagnosing conditions like major depressive disorder (MDD) can be broad, potentially leading to overdiagnosis and, consequently, overprescription.
  2. Prescribing Practices:
    • Primary care physicians write most antidepressant prescriptions, often without thorough psychiatric evaluation.
    • Some prescriptions are written for mild cases of depression or subclinical symptoms where psychotherapy or lifestyle changes might suffice.
  3. Off-Label Use:
    • Antidepressants are frequently prescribed off-label for conditions like insomnia, chronic pain, or anxiety, contributing to their high utilization.
  4. Pharmaceutical Influence:
    • Aggressive marketing by pharmaceutical companies has historically played a role in increasing antidepressant use.

Arguments Against Overprescription

  1. Underdiagnosis and Undertreatment:
    • Despite high prescription rates, many individuals with diagnosable depression or anxiety disorders go untreated, particularly in underserved populations.
    • Stigma and access barriers often prevent people from seeking care.
  2. Increasing Mental Health Awareness:
    • Growing awareness of mental health issues may explain rising prescription rates, as more people seek help for legitimate conditions.
  3. Non-Psychiatric Indications:
    • Antidepressants are also effective for non-depressive disorders, like obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and chronic pain, which justifies some of their broader use.

Data on Antidepressant Use

According to surveys, about 1 in 8 Americans aged 18 and older take antidepressants, and usage is particularly high among women, especially those aged 40–59. While this might seem like a high prevalence, it may also reflect greater recognition and treatment of mental health issues.

Key Considerations

  • Patient-Centered Care: The decision to prescribe antidepressants should be tailored to the individual, based on a comprehensive assessment of their symptoms and needs.
  • Access to Alternatives: Many individuals lack access to evidence-based non-pharmacological treatments like psychotherapy due to cost, availability, or stigma, making antidepressants a more feasible option.
  • Role of Education: Educating both prescribers and patients on appropriate use can reduce potential overprescription.
0

Breaking the Anxiety Barrier: LSD a Game-Changer for GAD?

Should LSD be considered a treatment for generalized anxiety disorder (GAD)? The results from MindMed’s Phase 2b study suggest it just might be. While this is only one study, and the FDA’s cautious stance on psychedelic-based treatments like MDMA raises questions about future approval, the findings are worth exploring. So, let’s dive in.

GAD is a fascinating and somewhat controversial diagnosis. Notably, the study excluded participants with major depressive disorder, a condition frequently comorbid with GAD, which raises interesting questions about the choice to isolate GAD. Some in the psychiatric field even challenge the validity of GAD as a distinct psychiatric disease, arguing it reflects broader distress rather than a discrete disorder.

Psychedelics like LSD are surging to the forefront of psychiatric research, largely because the field is starved for innovation. Decades of research and sophisticated drug development have yielded limited breakthroughs in understanding or treating psychiatric conditions. Meanwhile, society often clings to the hope that complex human behavior and mental health challenges can be reduced to something as simple as a pill you take every 12 weeks. The appeal of psychedelics lies in their potential to disrupt this paradigm—but can they deliver?

Key Findings:

  1. Dose-Dependent Response:
    • Patients receiving a higher dose (200 µg) of MM-120 showed rapid and sustained improvements in anxiety symptoms.
    • The reduction in anxiety symptoms was statistically significant compared to the placebo group.
  2. Speed of Onset:
    • Improvements were observed as early as two weeks post-dosing, suggesting a rapid therapeutic effect.
  3. Duration of Effect:
    • The anxiety-reducing effects lasted up to 12 weeks following a single administration, indicating long-lasting benefits.
  4. Safety Profile:
    • The treatment was generally well-tolerated, with mild to moderate adverse effects such as headache, nausea, and transient emotional changes. There were no reports of severe adverse events related to the study drug.
  5. Mechanistic Insights:
    • MM-120 appears to modulate serotonin 5-HT2A receptors, leading to enhanced neuroplasticity and emotional processing, which may underlie the observed clinical improvements.

I’m always interested in the study population and if the researchers selected a group of patients with prior psychedelic use. Here is what I found 

Participant Screening and Inclusion:

  1. Prior Psychedelic Use:
    • Some participants may have had previous experiences with psychedelics (e.g., LSD, psilocybin, MDMA), as long as such use did not interfere with the integrity of the study (e.g., recent or habitual use, which might influence tolerance or expectations).
    • Individuals with significant past psychedelic use might be excluded to minimize potential biases in response to the trial drug.
  2. Psychedelic-Naïve Participants:
    • The trial likely included a substantial proportion of participants who were psychedelic-naïve, meaning they had never used substances like LSD or psilocybin before.
    • This approach helps ensure that the observed therapeutic effects can be attributed to MM-120 rather than prior familiarity or psychological preparation for psychedelic experiences.

Why Prior Use Matters:

  • Expectation Bias:
    • Participants with past psychedelic experiences may anticipate certain effects, influencing subjective outcomes like anxiety reduction.
  • Safety and Tolerability:
    • Previous exposure to psychedelics might affect how participants tolerate or respond to the treatment.
  • Generalizability:
    • Including both psychedelic-naïve and experienced individuals helps make the findings applicable to a broader population.

Implications:

This study suggests that psychedelic-assisted therapy, especially with compounds like MM-120, has significant potential as a novel treatment for GAD, offering rapid and durable relief after just one dose. These findings pave the way for further research and larger-scale trials.

0

Psychiatry: Ahead of the Curve on Singulair’s Neuropsychiatric Risks

Psychiatry is often criticized for being “late to the table” when it comes to recognizing the broader impacts of medical treatments. However, in the case of Singulair (montelukast), psychiatry has been aware of its potential neuropsychiatric effects for quite some time.

Singulair, widely used for asthma and allergic rhinitis, has long been associated with side effects such as mood changes, anxiety, depression, and even suicidality. This connection has been documented for years, yet the broader medical community and regulatory bodies have taken time to fully address these risks.

Recently, the FDA issued a new warning aimed at heightening awareness of montelukast’s neuropsychiatric side effects. This update emphasizes the importance of assessing the risk-benefit ratio, particularly for patients with mild conditions where alternative treatments may suffice.

Psychiatry’s Role

Psychiatrists have long recognized and documented cases where montelukast seemed to exacerbate or trigger psychiatric symptoms. Many of us have seen patients whose mood instability or new-onset anxiety correlated with starting the medication, leading to its discontinuation and subsequent symptom improvement.

Why This Matters

This development underscores the value of psychiatry’s vigilance in identifying patterns that might initially go unnoticed in other fields. It’s also a reminder of the importance of collaboration between specialties to ensure patient safety.

Key Takeaways:

  • Patients and families: Be aware of the potential neuropsychiatric side effects of montelukast. Monitor mood, sleep, and behavior changes closely, especially in children.
  • Clinicians: Always evaluate the necessity of montelukast in mild cases and consider alternatives when possible. Open conversations with patients about these risks can be life-saving.
  • Psychiatrists: Continue advocating for the recognition of neuropsychiatric risks in non-psychiatric medications. Our input is crucial in ensuring patient safety.

Psychiatry wasn’t late to this table. In fact, we may have set it.

0

The Silent Crisis: Physician Suicide in the United States

I saw these magnets today on the refrigerator located in the physicians lounge and it seemed like a good reminder 

In the U.S., an estimated 300-400 physicians die by suicide each year, a staggering rate far higher than that of the general population. This crisis, largely unspoken in healthcare settings, underscores the immense pressures physicians face daily. The high expectations, long hours, emotional exhaustion, and the stigma around seeking mental health support create a dangerous environment where burnout can quickly spiral into severe mental health struggles.

Physicians are trained to endure, often putting others’ health before their own. But the costs of “pushing through” take a toll. Many feel they cannot safely reach out for help without risking their careers due to institutional stigma around mental health treatment. This cycle of isolation and suppressed emotion can lead to tragic outcomes.

Organizations are beginning to address this issue by implementing wellness programs, peer support systems, and confidential mental health resources, but more systemic changes are needed. Reducing the stigma around mental health support, reforming punitive policies, and fostering a culture of openness in medicine could be life-saving.

Physician suicide affects us all—it robs the healthcare system of dedicated professionals and leaves profound impacts on patients, families, and communities. It’s time to break the silence and actively support those who care for us.

0

The Culture of Burnout in Modern Medicine

Modern medicine has given rise to a new culture of burnout. As physicians, we are already high achievers—it’s a prerequisite to make it through the intense training. However, this constant push for relentless productivity often leads to feelings of exhaustion and disconnection. In medicine, the focus is always on doing more—seeing more patients, finishing more tasks, and achieving more outcomes each day.

With digital technology, we’re constantly connected, always on call. Patients, colleagues, and administrators reach out through calls, texts, and emails at all hours. The pressure to respond immediately leads to guilt when we can’t meet these demands, even when they’re unreasonable. The result? We push ourselves beyond our limits, sacrificing our own well-being in the process.

This grind leaves little room to rest or tend to our mental health. The importance of downtime is overlooked, even though it’s essential for long-term sustainability in our profession. But it’s time we rethink the culture of busyness and productivity. We need to start focusing on slowing down, with an emphasis on not staying busy for the sake of being busy.

If you’re like me, you’ve probably tried this, only to find your mind immediately wandering to the next thing you need to do. The challenge is real. But to reclaim a deeper sense of meaning and purpose in both our personal and professional lives, we must commit to this change. By slowing down, we can begin to find more peace, love, and joy in our day-to-day activities.

Let’s reclaim our lives—it’s long overdue

0

Tragic final words of doctor, 33, before he died by suicide

The tragic loss of a 33-year-old ophthalmology resident by suicide is a heartbreaking reminder of the immense pressures faced by those in the medical field. Residency, known for its intense demands and long hours, often leaves little room for self-care, mental health support, and the emotional toll that comes with caring for others. This devastating event highlights the urgent need for systemic changes in medical training and work environments, ensuring that mental health resources are accessible, stigma is reduced, and medical professionals receive the support they need. Our hearts go out to the family, friends, and colleagues affected by this tragedy.

As a doctor myself, I ask you—who hasn’t felt like they’re running on empty at one point or another during their training or career? The #burnout in this profession is as real as it gets. It can destroy your life, ruin time with your family, and, in the worst cases, end your life. Are we really the ones who are sick, or are we just products of a sick society? We need to do better for each other.

0

Understanding Anxiety: My Personal Experience as a Medical Student

This reminds me a lot of the depression question. Patients often tell me, “Dr. Rossi, you don’t know what it’s like to be anxious.”

I usually have a quiet chuckle to myself because anxiety is something everyone experiences. It’s a natural part of life. We all have areas where we feel competent, and others where we feel out of our depth. It’s in those areas, the places where we feel uncertain or inadequate, that anxiety can really interfere with our ability to function.

My most challenging personal experience with anxiety happened during the infamous 4th term of medical school at St. George’s University. By this point, you’ve survived the first year and are well into the second. However, this term is notorious, and it often feels like the school uses it to weed out students—which, in my opinion, is a bit unethical. The structure of my routine completely changed. More requirements, longer lab hours, and less time to study. The familiar rhythm I had relied on to keep up was suddenly turned on its head.

Throughout that term, I was constantly on edge, overwhelmed by the pressure that all my hard work could slip away at any moment. I still vividly remember the first time I experienced a panic attack. It was early morning; I woke up drenched in sweat, my heart racing, and I couldn’t catch my breath. I was scared enough to go to the university clinic, and that’s when I found out it was a panic attack.

That experience taught me firsthand what anxiety truly feels like. It’s not just a fleeting worry—it can become physical, paralyzing, and all-consuming. When I talk to patients about anxiety, it’s from a place of understanding. Anxiety doesn’t discriminate, and it certainly doesn’t mean we’re incapable—just human.

0

Powered by WordPress.com.

Up ↑